CPA
ZYME icon

Capital Performance Advisors’s Zymeworks ZYME Stock Holding History

Capital Performance Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$188 – 2774
2024
Q3 		$188 Buy
+15
New +$163 ﹤0.01% 2571

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Capital Performance Advisors's ZYME Position: Q4 2024 in Review

Capital Performance Advisors sold out of Zymeworks (ZYME) in Q4 2024, closing a stake of 15 shares — an estimated $188 sold.

Capital Performance Advisors first reported a position in ZYME in Q3 2024 and held it in 1 quarter. The position peaked at $188 in Q3 2024. 172 funds tracked by Wall St. Rank hold ZYME as of Q4 2024.

  • Capital Performance Advisors reported no remaining Zymeworks position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 15 Zymeworks shares in Q4 2024, an estimated $188.
  • Capital Performance Advisors first reported a position in Zymeworks in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Zymeworks position peaked at $188 in Q3 2024.
  • 172 funds tracked by Wall St. Rank held Zymeworks as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.